Pacific Biosciences Of California (PACB) Receivables - Net (2010 - 2026)

Pacific Biosciences Of California has reported Receivables - Net for 17 years, with the latest figure at $29.4 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables - Net fell 7.25% year-over-year to $29.4 million; the trailing twelve-month figure through Mar 2026 stood at $29.4 million (down 7.25% YoY), and the FY2025 full-year result was $35.4 million, up 28.79% from the prior year.
• Receivables - Net for Q1 2026 stood at $29.4 million, down from $35.4 million in the prior quarter.
• The five-year high for Receivables - Net was $36.6 million in Q4 2023, with the low at $18.8 million in Q4 2022.
• Average Receivables - Net over 5 years is $29.2 million, with a median of $29.6 million recorded in 2023.
• Year-over-year, Receivables - Net soared 115.81% in 2022 and declined 24.83% in 2024.
• Tracing PACB's Receivables - Net over 5 years: stood at $18.8 million in 2022, then soared by 94.91% to $36.6 million in 2023, then dropped by 24.83% to $27.5 million in 2024, then increased by 28.79% to $35.4 million in 2025, then fell by 17.2% to $29.4 million in 2026.
• The last three Receivables - Net figures came in at $29.4 million (Q1 2026), $35.4 million (Q4 2025), and $30.6 million (Q3 2025), per Business Quant data.

Peer Comparison